17 March 2026

Physiomics plc

("Physiomics" or the "Company")

Physiomics completes Placing to fund growth opportunities

Launch of WRAP Retail Offer

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it has completed a revised placing, conditional on admission to trading on AIM, of, in aggregate, £490,000.00 (gross) from the issue of 122,500,000 new ordinary shares (the "Placing Shares") at an issue price of £0.004 per Placing Share (the "Placing Price") through the Company's broker, Hybridan LLP (the "Placing"). The Placing Price represents a discount of approximately 14 per cent. to the mid-market closing price of an existing ordinary share on 16 March 2026 (being the latest practicable date prior to this announcement).

The Company will also shortly be launching a revised retail offering to the Company's existing shareholders to raise up to an additional £110,000.00 by way of the issue of a further 27,500,000 new ordinary shares (the "WRAP Retail Offer Shares") at the Placing Price.

The placing and retail offer previously announced by the Company on 10 March 2026 have been cancelled in substitution for the placing announced by way of this announcement. The cancellation of the previous placing followed a review by the Board of the terms and structure of that placing and the later receipt by the Company on 13 March 2026 of a shareholder requisition under section 303 of the Companies Act 2006, details of which are set out in the Company's announcement yesterday. The Board considered it appropriate in these circumstances to relaunch the placing on revised terms, at a price of £0.004 per share, which represents an improvement on the price of the cancelled placing and reflects the level of investor demand received. It is noted that, as the Company's existing share issuance authorities are sufficient to cover the issue of the Placing Shares and the maximum number of WRAP Retail Offer Shares, it is intended that the General Meeting called for 7 April 2026, as announced on 10 March 2026, will be cancelled. The Board believes the Placing is in the best interests of the Company and its shareholders as a whole.

In order to further develop its business and continue its growth trajectory, the Company is raising funds to carry out the following activities and for general working capital:

·    Consulting Services (Modelling & Simulation and Biometrics)

o  Investment in business development and marketing to expand offering across both service lines, including further development of later clinical phases and engagement of large biopharmaceutical companies and contract research organisations; and

o  Expansion of internal capabilities to support both services, including development of new processes and data management solutions to support the expanding offerings.

·    Personalised Medicine Tool Development

o  Continue development of the Company's Personalised Dosing Software.

·    Corporate

o  Exploration of strategic options to accelerate growth of modelling and biometrics services and creation of new service-lines.

The Company has made significant progress since its last placing in February 2025, including:

·    Reporting a 46% year-on-year growth of total income for the financial year ending 30 June 2025 and reporting a record half-year for total income for the six-month period ending 31 December 2025. To date in FY26, the Company has twice exceeded its best monthly revenue in comparison to FY 2025 with one month achieving over £110k.

·    Appointment of Mr Jesse Thissen as Head of Biometrics and the Company's first four contract awards for this new service line.

·    Continued expansion of the modelling and simulation service line into new therapeutic areas, with projects supporting the development of new drugs targeting arthritis, chronic obstructive pulmonary disease, coeliac disease, and infectious diseases.

·    Continued diversification of client base, whilst still winning new business with long-standing relationships such as Numab Therapeutics.

·    Implementation of the Company's Personalised Dosing Software onto the DoseMeRx platform and expanded relationship with DoseMe Inc.

·    One peer-reviewed scientific article was published in partnership with Ankyra Therapeutics, accompanied by several thought leadership pieces and blog posts.

Retail Offering:

The Company is pleased to announce that a retail offer to existing shareholders will be shortly launched via the Winterflood Retail Access Platform ("WRAP"), to raise up to an additional £110,000.00 (the "WRAP Retail Offer"), through the issue of up to 27,500,000 new ordinary shares (the "WRAP Retail Offer Shares"), at the Placing Price.

The proceeds of the WRAP Retail Offer will be utilised in the same way as the proceeds of the Placing. For the avoidance of doubt, the WRAP Retail Offer is not part of the Placing. Completion of the WRAP Retail Offer is conditional, inter alia, upon the completion of the Placing, but completion of the Placing is not conditional on the completion of the WRAP Retail Offer. The WRAP Retail Offer is conditional on the WRAP Retail Offer Shares being admitted to trading.

The Company values its shareholder base and believes that it is appropriate to provide its existing retail shareholders in the United Kingdom the opportunity to participate in its fundraising.

The WRAP Retail Offer is expected to close at midday on 18 March 2026.

Admission and Total Voting Rights

Application will be made for the Placing Shares to be issued pursuant to the Placing and the WRAP Retail Offer Shares to be issued pursuant to the WRAP Retail Offer and each to be admitted to trading on AIM and dealing is expected to commence on or around 20 March 2026 ("Admission"). A further announcement regarding the enlarged issued share capital for the purposes of the Financial Conduct Authority's Disclosure Guidance and Transparency Rules will be made following completion of the Placing and the WRAP Retail Offer.

Dr Peter Sargent, CEO, commented:

"The Board is delighted by the continued support from our long-term shareholders who have decided to back the Company at a higher price than our previously announced fundraise on 10^th March. This is validation that our growth plans are supported, and Directors believe that this growth will continue and that the Company is on track to meet market expectations for this current year, which would represent a record year for total income of 27% growth based on market expectations."

Enquiries:

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Strand Hanson Limited (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018 as amended by virtue of the Market Abuse (Amendment) (EU Exit) Regulations 2019. Upon publication of this announcement, this inside information is now considered to be in the public domain.

The Directors of the Company accept responsibility for the content of this announcement.

Notes to Editor

About Physiomics

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 140 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.